241 related articles for article (PubMed ID: 27142386)
21. Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials.
Denkert C; Seither F; Schneeweiss A; Link T; Blohmer JU; Just M; Wimberger P; Forberger A; Tesch H; Jackisch C; Schmatloch S; Reinisch M; Solomayer EF; Schmitt WD; Hanusch C; Fasching PA; Lübbe K; Solbach C; Huober J; Rhiem K; Marmé F; Reimer T; Schmidt M; Sinn BV; Janni W; Stickeler E; Michel L; Stötzer O; Hahnen E; Furlanetto J; Seiler S; Nekljudova V; Untch M; Loibl S
Lancet Oncol; 2021 Aug; 22(8):1151-1161. PubMed ID: 34252375
[TBL] [Abstract][Full Text] [Related]
22. Optimal use of anthracycline-free perioperative chemotherapy in HER2-positive breast cancer patients.
Watanuki R; Hayashida T; Kawai Y; Kikuchi M; Nakashoji A; Yokoe T; Toyota T; Seki T; Takahashi M; Kitagawa Y
Int J Clin Oncol; 2019 Jul; 24(7):807-814. PubMed ID: 30810890
[TBL] [Abstract][Full Text] [Related]
23. A phase II trial to assess efficacy and safety of afatinib in extensively pretreated patients with HER2-negative metastatic breast cancer.
Schuler M; Awada A; Harter P; Canon JL; Possinger K; Schmidt M; De Grève J; Neven P; Dirix L; Jonat W; Beckmann MW; Schütte J; Fasching PA; Gottschalk N; Besse-Hammer T; Fleischer F; Wind S; Uttenreuther-Fischer M; Piccart M; Harbeck N
Breast Cancer Res Treat; 2012 Aug; 134(3):1149-59. PubMed ID: 22763464
[TBL] [Abstract][Full Text] [Related]
24. Citral induced apoptosis in MDA-MB-231 spheroid cells.
Nigjeh SE; Yeap SK; Nordin N; Kamalideghan B; Ky H; Rosli R
BMC Complement Altern Med; 2018 Feb; 18(1):56. PubMed ID: 29433490
[TBL] [Abstract][Full Text] [Related]
25. MAP3K1 expression is associated with progression and poor prognosis of hormone receptor-positive, HER2-negative early-stage breast cancer.
Kuo SH; Wei MF; Lee YH; Lin JC; Yang WC; Yang SY; Huang CS
Cell Oncol (Dordr); 2023 Oct; 46(5):1213-1234. PubMed ID: 37166744
[TBL] [Abstract][Full Text] [Related]
26. Risk of Positive Sentinel Lymph Node After Neoadjuvant Systemic Therapy in Clinically Node-Negative Breast Cancer: Implications for Postmastectomy Radiation Therapy and Immediate Breast Reconstruction.
Samiei S; van Kaathoven BN; Boersma L; Granzier RWY; Siesling S; Engelen SME; de Munck L; van Kuijk SMJ; van der Hulst RRJW; Lobbes MBI; Smidt ML; van Nijnatten TJA
Ann Surg Oncol; 2019 Nov; 26(12):3902-3909. PubMed ID: 31359276
[TBL] [Abstract][Full Text] [Related]
27. Prognostic Value of Intrinsic Subtypes in Hormone Receptor-Positive Metastatic Breast Cancer Treated With Letrozole With or Without Lapatinib.
Prat A; Cheang MC; Galván P; Nuciforo P; Paré L; Adamo B; Muñoz M; Viladot M; Press MF; Gagnon R; Ellis C; Johnston S
JAMA Oncol; 2016 Oct; 2(10):1287-1294. PubMed ID: 27281556
[TBL] [Abstract][Full Text] [Related]
28. Tumor selective cytotoxic action of a thiomorpholin hydroxamate inhibitor (TMI-1) in breast cancer.
Mezil L; Berruyer-Pouyet C; Cabaud O; Josselin E; Combes S; Brunel JM; Viens P; Collette Y; Birnbaum D; Lopez M
PLoS One; 2012; 7(9):e43409. PubMed ID: 23028451
[TBL] [Abstract][Full Text] [Related]
29. Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline.
Korde LA; Somerfield MR; Carey LA; Crews JR; Denduluri N; Hwang ES; Khan SA; Loibl S; Morris EA; Perez A; Regan MM; Spears PA; Sudheendra PK; Symmans WF; Yung RL; Harvey BE; Hershman DL
J Clin Oncol; 2021 May; 39(13):1485-1505. PubMed ID: 33507815
[TBL] [Abstract][Full Text] [Related]
30. HER2-associated radioresistance of breast cancer stem cells isolated from HER2-negative breast cancer cells.
Duru N; Fan M; Candas D; Menaa C; Liu HC; Nantajit D; Wen Y; Xiao K; Eldridge A; Chromy BA; Li S; Spitz DR; Lam KS; Wicha MS; Li JJ
Clin Cancer Res; 2012 Dec; 18(24):6634-47. PubMed ID: 23091114
[TBL] [Abstract][Full Text] [Related]
31. Development and verification of a three-dimensional (3D) breast cancer tumor model composed of circulating tumor cell (CTC) subsets.
Anil-Inevi M; Sağlam-Metiner P; Kabak EC; Gulce-Iz S
Mol Biol Rep; 2020 Jan; 47(1):97-109. PubMed ID: 31583566
[TBL] [Abstract][Full Text] [Related]
32. Correlation between the in vitro ATP-based chemosensitivity assay and HER2/neu expression in women with breast cancer.
Woo SU; Bae JW; Kim HG; Choi SH; Kang DH; Lee JB; Koo BW
J Int Med Res; 2007; 35(6):753-61. PubMed ID: 18034988
[TBL] [Abstract][Full Text] [Related]
33. Automated Assessment of Cancer Drug Efficacy On Breast Tumor Spheroids in Aggrewell™400 Plates Using Image Cytometry.
Mukundan S; Bell J; Teryek M; Hernandez C; Love AC; Parekkadan B; Chan LL
J Fluoresc; 2022 Mar; 32(2):521-531. PubMed ID: 34989923
[TBL] [Abstract][Full Text] [Related]
34. Three-dimensional lung tumor microenvironment modulates therapeutic compound responsiveness in vitro--implication for drug development.
Ekert JE; Johnson K; Strake B; Pardinas J; Jarantow S; Perkinson R; Colter DC
PLoS One; 2014; 9(3):e92248. PubMed ID: 24638075
[TBL] [Abstract][Full Text] [Related]
35. Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial.
Salgado R; Denkert C; Campbell C; Savas P; Nuciforo P; Aura C; de Azambuja E; Eidtmann H; Ellis CE; Baselga J; Piccart-Gebhart MJ; Michiels S; Bradbury I; Sotiriou C; Loi S
JAMA Oncol; 2015 Jul; 1(4):448-54. PubMed ID: 26181252
[TBL] [Abstract][Full Text] [Related]
36. A Phase Ib Trial of Durvalumab in Combination with Trastuzumab in HER2-Positive Metastatic Breast Cancer (CCTG IND.229).
Chia S; Bedard PL; Hilton J; Amir E; Gelmon K; Goodwin R; Villa D; Cabanero M; Tu D; Tsao M; Seymour L
Oncologist; 2019 Nov; 24(11):1439-1445. PubMed ID: 31420468
[TBL] [Abstract][Full Text] [Related]
37. Everolimus plus Exemestane for Hormone Receptor-Positive Advanced Breast Cancer: A PAM50 Intrinsic Subtype Analysis of BOLERO-2.
Prat A; Brase JC; Cheng Y; Nuciforo P; Paré L; Pascual T; Martínez D; Galván P; Vidal M; Adamo B; Hortobagyi GN; Baselga J; Ciruelos E
Oncologist; 2019 Jul; 24(7):893-900. PubMed ID: 30679318
[TBL] [Abstract][Full Text] [Related]
38. Patient-derived tumor spheroid cultures as a promising tool to assist personalized therapeutic decisions in breast cancer.
Hofmann S; Cohen-Harazi R; Maizels Y; Koman I
Transl Cancer Res; 2022 Jan; 11(1):134-147. PubMed ID: 35261891
[TBL] [Abstract][Full Text] [Related]
39. Breast Cancer Spheroids Reveal a Differential Cancer Stem Cell Response to Chemotherapeutic Treatment.
Reynolds DS; Tevis KM; Blessing WA; Colson YL; Zaman MH; Grinstaff MW
Sci Rep; 2017 Sep; 7(1):10382. PubMed ID: 28871147
[TBL] [Abstract][Full Text] [Related]
40. Changes in tumor expression of HER2 and hormone receptors status after neoadjuvant chemotherapy in 21,755 patients from the Japanese breast cancer registry.
Niikura N; Tomotaki A; Miyata H; Iwamoto T; Kawai M; Anan K; Hayashi N; Aogi K; Ishida T; Masuoka H; Iijima K; Masuda S; Tsugawa K; Kinoshita T; Nakamura S; Tokuda Y
Ann Oncol; 2016 Mar; 27(3):480-7. PubMed ID: 26704052
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
